Latest News

Major announcement: Pharmac Initiates Consultation to fund Ocrelizumab for Primary Progressive MS.

June 22, 2023 | Advocacy, Funding, Media, Progressive

Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to […]


Addressing the unmet need

September 14, 2022 | Advocacy, Progressive, Treatments

Currently, only approximately 1900 of the over 4130 New Zealanders diagnosed with MS are able to access funded Disease Modifying Therapies (DMTs). In particular, those with progressive forms of MS, Secondary (SPMS) and Primary Progressive MS (PPMS), have extremely limited […]


Calling all people with Secondary Progressive MS

July 26, 2022 | Life with MS, Progressive, Research

Multiple Sclerosis NZ is currently in the process of providing information to Pharmac regarding the high unmet need of those with Secondary Progressive MS. A new treatment, Siponimod (Mayzent), is currently under review and due to be assessed by PTAC […]


Fatigue in Progressive MS – Webcast

November 3, 2021 | Education, Event, Life with MS, Progressive, Research

Fatigue is one of the most common, troubling symptoms experienced by people with progressive MS. For many people, it is the symptom that affects them most. Join MSIF to learn about the latest advances in treatment and research in fatigue […]


ECTRIMS 2021 Conference Review

November 3, 2021 | Education, Event, Progressive, Uncategorised

The 37th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) was held online recently. The scientific programme comprised well-known session formats such as Scientific Sessions, Hot Topics and Meet the Experts, as well as live discussions […]